E3

Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?

ESC Cardio-Oncology 2026: Cancer therapy is getting smarter. Cardiac protection is still playing catch-up.

Cholesterol prevention is moving earlier. Is Europe ready to treat inherited risk before adulthood?

Surviving Cancer Is Not the Same as Being Recovered

Colon Cancer Immunotherapy Moves Into the Adjuvant Access Test

Personalised cardiology cannot succeed if women’s hearts still follow men’s pathways

AstraZeneca’s Baxfendy opens a new front in uncontrolled hypertension, but monitoring will decide who benefits

Huntington’s Gene Therapy Moves Back Toward the FDA Door

Precision cardiology is becoming the new oncology. Policy and reimbursement must catch up
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
